What is HC Wainwright's Estimate for Vericel Q4 Earnings?

Key Points

• HC Wainwright lifted its Q4 2026 EPS estimate for Vericel to $0.46 from $0.43, while maintaining a Buy rating and a $64 price target.
• Vericel’s latest quarterly results were better than expected, with EPS of -$0.12 versus an expected -$0.15 and revenue of $68.43 million, which also topped estimates and rose 30.1% year over year.
• Analyst sentiment remains constructive overall: the stock has a Moderate Buy consensus, and Vericel recently raised full-year 2026 revenue guidance to $326 million-$336 million.

Vericel Corporation (NASDAQ:VCEL - Free Report) - HC Wainwright raised their Q4 2026 earnings per share (EPS) estimates for Vericel in a report issued on Friday, May 8th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.46 per share for the quarter, up from their previous estimate of $0.43. HC Wainwright currently has a "Buy" rating and a $64.00 price target on the stock. The consensus estimate for Vericel's current full-year earnings is $0.45 per share. HC Wainwright also issued estimates for Vericel's Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at $0.16 EPS, Q3 2027 earnings at $0.14 EPS and Q4 2027 earnings at $0.51 EPS.

Vericel (NASDAQ:VCEL - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.03. Vericel had a return on equity of 6.41% and a net margin of 7.35%.The business had revenue of $68.43 million for the quarter, compared to analysts' expectations of $63.68 million. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. The company's revenue was up 30.1% compared to the same quarter last year.

VCEL has been the subject of several other reports. Leerink Partners reissued an "outperform" rating and issued a $46.00 price objective on shares of Vericel in a report on Tuesday, March 10th. Wall Street Zen raised Vericel from a "hold" rating to a "buy" rating in a report on Saturday, March 28th. Finally, Truist Financial lowered their price objective on Vericel from $48.00 to $42.00 and set a "buy" rating for the company in a report on Wednesday, April 15th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $55.40.

Vericel Price Performance

Shares of Vericel stock opened at $33.46 on Monday. The firm has a market cap of $1.71 billion, a P/E ratio of 79.67 and a beta of 1.15. Vericel has a fifty-two week low of $28.95 and a fifty-two week high of $45.97. The business has a 50-day moving average price of $33.93 and a 200 day moving average price of $36.20.

Hedge Funds Weigh In On Vericel

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. William Blair Investment Management LLC grew its holdings in Vericel by 90.3% in the 3rd quarter. William Blair Investment Management LLC now owns 2,210,929 shares of the biotechnology company's stock worth $69,578,000 after buying an additional 1,048,864 shares in the last quarter. State Street Corp grew its holdings in Vericel by 12.7% in the 4th quarter. State Street Corp now owns 3,163,922 shares of the biotechnology company's stock worth $113,933,000 after buying an additional 356,680 shares in the last quarter. Aberdeen Group plc grew its holdings in Vericel by 159.5% in the 3rd quarter. Aberdeen Group plc now owns 542,866 shares of the biotechnology company's stock worth $17,084,000 after buying an additional 333,649 shares in the last quarter. GW&K Investment Management LLC grew its holdings in Vericel by 22.5% in the 4th quarter. GW&K Investment Management LLC now owns 1,580,967 shares of the biotechnology company's stock worth $56,931,000 after buying an additional 290,795 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Vericel by 133.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 497,167 shares of the biotechnology company's stock worth $17,903,000 after buying an additional 284,305 shares in the last quarter.

Insider Activity at Vericel

In other news, insider Jonathan Mark Hopper sold 3,472 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $121,520.00. Following the completion of the transaction, the insider directly owned 75,556 shares of the company's stock, valued at approximately $2,644,460. This represents a 4.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 7.60% of the company's stock.

Trending Headlines about Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q1 revenue of $68.4 million, up 30% year over year and above expectations, with strong growth in both MACI and Burn Care. Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
• Positive Sentiment: The company beat Q1 earnings estimates, posting a loss of $0.12 per share versus the expected loss of $0.15, while adjusted EBITDA surged and free cash flow turned positive. Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
• Positive Sentiment: Vericel raised full-year 2026 revenue guidance to $326 million-$336 million from $316 million-$326 million, signaling confidence in continued growth. Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
• Neutral Sentiment: Management highlighted record first-quarter performance, BARDA support for NexoBrid, and FDA approval for MACI manufacturing at the new facility, which could support longer-term growth but are not immediate revenue drivers. Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Despite the strong top-line growth, Vericel still posted a net loss of $6.3 million, and operating expenses rose as the company expanded its sales force and manufacturing footprint. Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company's expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.